Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 352

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 352
---
 accessed through, NLS’s website or the SEC website is not part of this proxy statement/prospectus. The website address has been included in this proxy statement/prospectus solely as an inactive textual reference. NLS is an EGC. As such, NLS is eligible to, and intends to, take advantage of certain exemptions from various reporting requirements applicable to other public companies that are not “emerging growth companies” such as not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes -OxleyAct. NLS could remain an EGC for up to five years, or until the earliest of (a) the last day of the first fiscal year in which NLS’s annual gross revenues exceeds $1.235billion, (b) the date that NLS becomes a “large accelerated filer” as defined in Rule 12b -2under the Exchange Act, which would occur if the market value of NLS Common Shares that is held by non -affiliatesexceeds $700million as of the last business day of its most recently completed second fiscal quarter, or (c) the date on which NLS issued more than $1billion in nonconvertible debt during the preceding three -yearperiod. NLS is a foreign private issuer as defined by the rules under the Securities Act and the Exchange Act. NLS’s status as a foreign private issuer also exempts it from compliance with certain laws and regulations of the SEC and certain regulations of Nasdaq, including the proxy rules, the short -swingprofits recapture rules, and certain governance requirements such as independent director oversight of the nomination of directors and executive compensation. In addition, NLS is not required to file annual, quarterly and current reports and financial statements with the SEC as frequently or as promptly as U.S. domestic companies registered under the Exchange Act. Starting the last quarter of 2023, NLS began to adjust its workforce, primarily comprised of consultants. On March20, 2024, NLS announced that it had secured Exclusive Global License for Next -GenerationNon -SulfonamideDual Orexin Agonist Platform. On March22, 2024, NLS announced the closing of $1.75 Million Registered Direct Offering. After the consummation of the Merger, NLS’s principal executive office will remain at The Circle6, 8058 Zurich, Switzerland, Tel: +41.44.512.2150. Business Overview NLS is a clinical